VA Technology Transfer has role in malaria invention
When a VA researcher invents a new drug or technology, it won't help Veterans or anyone else unless it makes it out of the lab. That's where VA's
Technology Transfer Program comes in.
The program works to protect the intellectual property developed at VA and help get it commercialized. This usually involves a private company willing to
invest in the technology and provide further development, manufacturing, and marketing. Typically, VA shares in some of the eventual proceeds, as do the
inventors, and sometimes their universities, but the details vary depending on the exact legal agreement that is struck.
In the case of Riscoe's malaria work at the Portland VA, the researcher has three inventions registered with VA, all related to the experimental malaria
drug ELQ-300. His academic home, Oregon Health and Science University, is taking the lead on patenting and licensing the inventions, but VA is a joint
The details were worked out in a contract, called a Cooperative Technology Administration Agreement, that VA Technology Transfer negotiated with the
university: "It dictates the parameters for how jointly owned intellectual property is handled, including the sharing and distribution of any royalty
income that the inventions may garner," says Lee Sylvers, PhD, a technology transfer specialist with VA.
Sylvers says such arrangements are "the major route to translating VA innovations into products and services that ultimately impact the health care of
Veterans and others."
For more details on the VA Technology Transfer Program, including a list of inventions for which VA is seeking commercial partners, visit: www.research.va.gov/programs/tech_transfer.